Company: DNLI
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001714899-25-000170
Chunk: 186

Company: Denali Therapeutics Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 186
---
 — Accounts payable(43)4,523 Accruals and other current liabilities(14,151)(18,496)Deferred research and development funding liability16,176 10,340 Net cash used in operating activities(206,766)(204,840)Investing activitiesPurchases of marketable securities(137,926)(955,802)Maturities and sales of marketable securities323,965 608,120 Purchases of property and equipment(9,356)(6,936)Net cash provided by (used in) investing activities176,683 (354,618)Financing activitiesProceeds from issuance of common stock and pre-funded warrants, net of issuance costs of $480— 499,253 Proceeds from exercise of awards under equity incentive plans4,652 7,778 Payments for finance lease right-of-use asset(6,791)— Net cash (used in) provided by financing activities(2,139)507,031 Net decrease in cash, cash equivalents and restricted cash(32,222)(52,427)Cash, cash equivalents and restricted cash at beginning of period176,535 128,681 Cash, cash equivalents and restricted cash at end of period$144,313 $76,254 Supplemental disclosures of cash flow informationEquity consideration received in the divestiture of small molecule programs (Note 10)$— $15,000 

 See accompanying notes to unaudited condensed consolidated financial statements.

6

Denali Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements 

(Unaudited)

1.    Significant Accounting Policies

Organization and Description of BusinessDenali Therapeutics Inc. ("Denali" or the “Company”) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases and lysosomal storage diseases. The Company is headquartered in South San Francisco, California.Basis of PresentationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of the Securities and Exchange Commission ("SEC") Regulation S-X for interim financial information. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December